The device was not returned for evaluation.
A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.
The reported patient effect of dizziness is listed in the xience sierra, everolimus eluting coronary stent system (eecss), electronic instructions for use as a known patient effect of coronary stenting procedures.
Based on the information reviewed, there is no indication of a product quality issue.
A conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined; however, the subsequent treatment appears to be related to the operational context of the procedure.
There is no indication of a product quality issue with respect to manufacture, design or labeling of the device.
Na.
|